Jaguar Health Reduces $3M Debt, Extinguishes 48,212 Warrants and Extends $7M Credit
Jaguar Health restructured obligations with Chicago Venture Partners, cutting $3 million (10%) in royalty and debt, extinguishing 48,212 warrants and extending a $7 million revolving credit line maturity by three years with no debt due before July 2026. The company continues development of crofelemer for rare intestinal failure while seeking non-dilutive licensing partnerships.
1. Restructuring Details
Jaguar Health negotiated with Chicago Venture Partners to reduce its royalty and affiliate debt obligations by approximately $3 million, representing a 10% cut. The company also extinguished 48,212 warrants, extended the maturity of a $7 million secured revolving credit line by three years and eliminated any debt maturities before July 2026.
2. Operational Focus on Crofelemer
Jaguar remains focused on its global development program for crofelemer for rare intestinal failure indications, targeting clinical proof-of-concept milestones. Management is engaging potential license partners to secure non-dilutive funding to advance clinical and commercialization efforts.